Therapy Areas: Central Nervous System
AbbVie, Gedeon Richter Forge Collaboration in Neuropsychiatric Diseases
11 March 2022 - - US-based pharmaceutical company AbbVie (NYSE: ABBV) and Hungary-based Gedeon Richter plc have inked a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases, the companies said.

The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development.

AbbVie and Richter have collaborated for 15 years on Central Nervous System projects, including globally launched products such as cariprazine (VRAYLAR / REAGILA).

Under the terms of the agreement, the collaboration includes both preclinical and clinical R and D activities with shared financing by the parties.

Richter will receive an upfront cash payment, along with potential future development, regulatory and commercialization milestones.

In addition, Richter may also receive sales-based royalties. AbbVie will have worldwide commercialization rights except for traditional markets of Richter, such as geographic Europe, Russia, other CIS countries and Vietnam.

The transaction is expected to close in 2Q22, subject to the satisfaction of customary closing conditions, including applicable regulatory approvals.

Gedeon Richter plc, headquartered in Budapest/Hungary, is a pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China and in Latin America.


Related Headlines